Transl Lung Cancer Res: A randomized phase II study comparing the efficacy of bevacizumab combined with different platinum-based chemotherapy regimens in the treatment of advanced non-squamous non-small cell lung cancer (nsNSCLC)

Atezolizumab combined with bevacizumab + platinum-based chemotherapy is the standard of care for advanced non-squamous non-small cell lung cancer (nsNSCLC)
.

Recently, a randomized phase II study was conducted by a Japanese team to determine the most effective platinum-based combination regimen for future studies in combination with atezolizumab to further improve patient outcomes

Atezolizumab combined with bevacizumab + platinum-based chemotherapy is the standard of care for advanced non-squamous non-small cell lung cancer (nsNSCLC)

The study included patients with untreated advanced or relapsed nsNSCLC who were randomly assigned to cisplatin (75 mg/m ² ) + pemetrexed (500 mg/m ² ) + bevacizumab (15 mg/kg) (CisPemBev) , followed by pemetrexed + bevacizumab (PemBev ) maintenance (N=132) or carboplatin (AUC 6 mg/mL/min) + paclitaxel (200 mg/m ² ) + bevacizumab (15 mg/kg) (CarPacBev), followed by bevacizumab (Bev) maintenance (N=67)
.

The primary study endpoint was PFS, and secondary study endpoints were OS, ORR and AEs

The study included patients with untreated advanced or relapsed nsNSCLC who were randomly assigned to cisplatin (75 mg/m ² ) + pemetrexed (500 mg/m ² ) + bevacizumab (15 mg/kg) (CisPemBev) , followed by pemetrexed + bevacizumab (PemBev ) maintenance (N=132) or carboplatin (AUC 6 mg/mL/min) + paclitaxel (200 mg/m ² ) + bevacizumab (15 mg/kg) (CarPacBev), followed by bevacizumab (Bev) maintenance (N=67)

From May 2014 to May 2016, 199 patients were randomly assigned to treatment with CisPemBev (N=132) or CarPacBev (N=67)

Investigator assessment showed that median progression-free survival (PFS) was longer in the Cispemv group compared with CarPacBev (HR 0.
634, 95% CI, 0.
464-0.
867; median PFS, 7.
4 months vs.
6.
8 months)
.

The median OS was 23.

Investigator assessment showed that median progression-free survival (PFS) was longer in the Cispemv group compared with CarPacBev (HR 0.

Forest plots of HRs for PFS and OS stratified by patient characteristics are shown
.

HRs for PFS and OS were lowest when the tumor was recurrent (0.

Forest plots of HRs for PFS and OS stratified by patient characteristics are shown

Grade ≥3 AEs were reported in 67% and 82% of patients in the Cispemv and CarPacBev groups, respectively
.

The most common grade 3 AEs (Cispemv/CarPacBev) were decreased neutrophil count (24%/64%), leukopenia (12%/30%), and hyponatremia (11%/9%)

Grade ≥3 AEs were reported in 67% and 82% of patients in the Cispemv and CarPacBev groups, respectively

In conclusion, the study shows that CisPem combined with Bev is more effective than CarPacBev in improving PFS in patients with advanced non-small cell lung cancer
.
Cispemv was also well tolerated in this patient population
.

In conclusion, the study shows that CisPem combined with Bev is more effective than CarPacBev in improving PFS in patients with advanced non-small cell lung cancer
.
Cispemv was also well tolerated in this patient population
.
Studies have shown that CisPem combined with Bev is more effective than CarPacBev in improving PFS in patients with advanced non-small cell lung cancer
.
Cispemv was also well tolerated in this patient population
.
Studies have shown that CisPem combined with Bev is more effective than CarPacBev in improving PFS in patients with advanced non-small cell lung cancer
.
Cispemv was also well tolerated in this patient population
.

 

Original source:

Original source:

Udagawa H, Sugiyama E, Harada T, Atagi S, Koyama R, Watanabe S, Nakamura Y, Harada D, Hataji O, Tanaka F, Kida H, Satouchi M, Maeno K, Inoue A, Yoh K, Yamane Y, Urata Y , Yoshioka H, ​​Yamanaka T, Goto K.
Bevacizumab plus platinum-based chemotherapy in advanced non-squamous non-small-cell lung cancer: a randomized, open-label phase 2 study (CLEAR).
Transl Lung Cancer Res 2021;10( 7): 3059-3070.
doi: 10.
21037/tlcr-21-240.

Udagawa H, Sugiyama E, Harada T, Atagi S, Koyama R, Watanabe S, Nakamura Y, Harada D, Hataji O, Tanaka F, Kida H, Satouchi M, Maeno K, Inoue A, Yoh K, Yamane Y, Urata Y , Yoshioka H, ​​Yamanaka T, Goto K.
Bevacizumab plus platinum-based chemotherapy in advanced non-squamous non-small-cell lung cancer: a randomized, open-label phase 2 study (CLEAR).
Transl Lung Cancer Res 2021;10( 7): 3059-3070.
doi: 10.
21037/tlcr-21-240.
Leave a message here